Literature DB >> 299884

Phorbol myristate acetate: a mitogen selective for a T-lymphocyte subpopulation.

J L Touraine, J W Hadden, F Touraine, E M Hadden, R Estensen, R A Good.   

Abstract

Phorbol myristate acetate (pma) is a potent mitogen for human peripheral blood lymphocytes (PBL) comparable to phytohemagglutinin (PHA) in potency. Inactivation of PHA-responsive lymphocytes by 5'-bromodeoxyuridine and light treatment left the PMA response intact and nice versa. Experiments separating lymphocytes by rosetting with sheep erythrocytes (SRBC) demonstrated that the PMA-responsive lymphocytes segregate with those that have a high affinity for SRBC to a greater than PHA- or concanavalin A (Con A)-responsive cells. These results indicate that a PMA-responsive population in human peripheral blood resides within the T-lymphocyte population and appears to have a high affinity for SRBC and to be distinct from that responding to PHA and Con A. PMA may be useful clinically to assay the size and function of the high affinity or "active" rosette population.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 299884      PMCID: PMC2180613          DOI: 10.1084/jem.145.2.460

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  11 in total

1.  Different Ly antigen phenotypes of in vitro induced helper and suppressor cells.

Authors:  M Feldmann; P C Beverley; M Dunkley; S Kontiainen
Journal:  Nature       Date:  1975-12-18       Impact factor: 49.962

2.  Thymosin: effects on normal human blood T-cells.

Authors:  J Wybran; A S Levin; H H Fudenberg; A L Goldstein
Journal:  Ann N Y Acad Sci       Date:  1975-02-28       Impact factor: 5.691

3.  Synergistic action of phorbol esters in mitogen-activated bovine lymphocytes.

Authors:  A M Mastro; G C Mueller
Journal:  Exp Cell Res       Date:  1974-09       Impact factor: 3.905

4.  Human lymphocyte-sheep erythrocyte rosette formation: some characteristics of the interaction.

Authors:  Z Bentwich; S D Douglas; F P Siegal; H G Kunkel
Journal:  Clin Immunol Immunopathol       Date:  1973-07

5.  Activation of cell membrane enzymes in the stimulation of cell division.

Authors:  A Sivak; B T Mossman; B L Van Duuren
Journal:  Biochem Biophys Res Commun       Date:  1972-01-31       Impact factor: 3.575

6.  Thymus-derived lymphocytes: humoral and cellular reactions distinguished by hydrocortisone.

Authors:  S Segal; I R Cohen; M Feldman
Journal:  Science       Date:  1972-03-10       Impact factor: 47.728

Review 7.  Tumor-promoting agents in two-stage carcinogenesis.

Authors:  B L Van Duuren
Journal:  Prog Exp Tumor Res       Date:  1969

8.  Modulation of lymphocyte mitogenesis.

Authors:  J L Wang; D A McClain; G M Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

9.  Functional subclasses of T-lymphocytes bearing different Ly antigens. I. The generation of functionally distinct T-cell subclasses is a differentiative process independent of antigen.

Authors:  H Cantor; E A Boyse
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

10.  Separation of helper T cells from suppressor T cells expressing different Ly components. I. Polyclonal activation: suppressor and helper activities are inherent properties of distinct T-cell subclasses.

Authors:  J Jandinski; H Cantor; T Tadakuma; D L Peavy; C W Pierce
Journal:  J Exp Med       Date:  1976-06-01       Impact factor: 14.307

View more
  39 in total

Review 1.  The yin and yang of protein kinase C-theta (PKCθ): a novel drug target for selective immunosuppression.

Authors:  Elizabeth Yan Zhang; Kok-Fai Kong; Amnon Altman
Journal:  Adv Pharmacol       Date:  2013

2.  Effect of occupational exposure to benzene on phytohaemagglutinin (PHA) stimulated lymphocytes in man.

Authors:  A Yardley-Jones; D Anderson; P Jenkinson
Journal:  Br J Ind Med       Date:  1988-08

3.  Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8+ T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency Reversal.

Authors:  Talia M Mota; Chase D McCann; Ali Danesh; Szu-Han Huang; Dean B Magat; Yanqin Ren; Louise Leyre; Tracy D Bui; Thomas M Rohwetter; Colin M Kovacs; Erika Benko; Lynsay MacLaren; Avery Wimpelberg; Christopher M Cannon; W David Hardy; Jeffrey T Safrit; R Brad Jones
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

4.  Phorbol ester treated chronic B lymphocytic leukaemia cells induce autologous T cell proliferation without generation of cytotoxic T cells.

Authors:  D Kabelitz; T H Tötterman; K Nilsson; M Gidlund
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

5.  12-O-Tetradecanoylphorbol-13-acetate (TPA) directly inhibits spontaneous immunoglobulin secretion by in vivo antigen-induced human lymphoblastoid B cells.

Authors:  J A Brieva; J S Louie; R H Stevens
Journal:  J Clin Immunol       Date:  1984-07       Impact factor: 8.317

6.  Effects of 12-o-tetradecanoyl-phorbol-13-acetate (TPA) on the colony growth of human T lymphocytes.

Authors:  R Foa; P Lusso; M T Fierro; M C Giubellino; M L Ferrando; L Pegoraro
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

7.  Specific receptors for phorbol esters in lymphoid cell populations: role in enhanced production of T-cell growth factor.

Authors:  J J Sando; M L Hilfiker; D S Salomon; J J Farrar
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

8.  Tumor promoter phorbol myristic acetate stimulates immunoglobulin secretion correlated with growth cessation in human B lymphocyte cell lines.

Authors:  P Ralph; T Kishimoto
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

9.  Studies on T-lymphocyte activation. I. Is competence inductions in thymocytes by phorbol myristate acetate, an accessory cell-independent event?

Authors:  T Diamantstein; M Klos; J Reimann
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

10.  Cytochalasin B is a potent mitogen for chronic lymphocytic leukemia cells in vitro.

Authors:  R A Larson; S Yachnin
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.